CCL5 and melanoma: Based on data from The Cancer Genome Atlas (TCGA), melanoma patients were divided into a PRELPhigh and PRELPlow group and associated with clinical parameters, expression of HLA class I APM and IFN-γ signal pathway components, CCL5 as well as the tumor immune infiltration.